NeuroPace (NASDAQ:NPCE) Stock Price Target Lowered at Cantor Fitzgerald

NeuroPace (NASDAQ:NPCE – Get Free Report) had its target price cut by Cantor Fitzgerald from $21.00 to $12.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Cantor Fitzgerald‘s target price would indicate a potential upside of 58.73% from the stock’s previous close.

A number of other analysts have also issued reports on NPCE. JPMorgan Chase & Co. lowered NeuroPace from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $20.00 to $9.00 in a research note on Friday. Weiss Ratings cut shares of NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. Guggenheim restated a “neutral” rating on shares of NeuroPace in a research report on Wednesday, July 29th. Wall Street Zen lowered NeuroPace from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Leerink Partners cut shares of NeuroPace from an “outperform” rating to a “market perform” rating and set a $7.00 price target on the stock. in a research report on Friday. Five research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $14.22.

Check Out Our Latest Analysis on NeuroPace

NeuroPace Price Performance

Shares of NASDAQ NPCE opened at $7.56 on Friday. The stock has a fifty day simple moving average of $13.21 and a two-hundred day simple moving average of $14.75. NeuroPace has a 1-year low of $5.46 and a 1-year high of $19.60. The firm has a market cap of $259.49 million, a price-to-earnings ratio of -13.50 and a beta of 1.98. The company has a current ratio of 5.26, a quick ratio of 4.09 and a debt-to-equity ratio of 5.15.

Institutional Trading of NeuroPace

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc bought a new position in shares of NeuroPace in the second quarter worth approximately $41,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of NeuroPace in the second quarter worth $157,000. Entropy Technologies LP purchased a new position in shares of NeuroPace in the third quarter worth $146,000. Diversified Trust Co bought a new stake in NeuroPace during the 3rd quarter valued at $153,000. Finally, Bank of America Corp DE bought a new stake in NeuroPace during the 2nd quarter valued at $322,000. Institutional investors own 78.83% of the company’s stock.

About NeuroPace

(Get Free Report)

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.

See Also

Analyst Recommendations for NeuroPace (NASDAQ:NPCE)

Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.